Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propranolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.71 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.71 |
| ▸ | HTR2B | P41595 | 3/20 | 0.71 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.71 |
| ▸ | HTR2A | P28223 | 3/20 | 0.71 |
| ▸ | HTR2C | P28335 | 3/20 | 0.71 |
| ▸ | HTR6 | P50406 | 3/20 | 0.71 |
| ▸ | SCN1A | P35498 | 2/20 | 0.71 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.71 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.71 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stearic Acid SCHEMBL11025256 | 1.00 | ADRB2 (0.71) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| Oleic Acid SCHEMBL2796171 | 0.94 | ADRB2 (0.64) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| Oleic Acid SCHEMBL2796167 | 0.94 | ADRB2 (0.64) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| Propranolol SCHEMBL5566676 | 0.88 | CYP2D6 (0.83) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| Propranolol SCHEMBL9715887 | 0.87 | ADRB2 (0.80) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| SCHEMBL11097608 | 0.87 | ADRB2 (0.63) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| Propranolol SCHEMBL28921627 | 0.86 | CYP2D6 (0.88) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| Propranolol SCHEMBL27713595 | 0.85 | ADRB2 (0.65) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| SCHEMBL10605795 | 0.85 | ADRB2 (0.64) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 | |
| Propranolol SCHEMBL28263189 | 0.84 | ADRB2 (0.95) | ADRB2CYP2D6ADRB1SIGMAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2001508027-A | — | — | 2001-06-19 | — | — | JP | claimed |
| EP-1024833-A1 | Pharmaceutical composition containing acid addition salt of basic drug | FARMARC NEDERLAND B.V. (NL) | 2000-08-09 | — | — | EP | claimed |
| CN-1230123-A | Inclusion complex containing indole selective serotonin agonist | FARMARC NEDERLAND BV (NL) | 1999-09-29 | — | — | CN | claimed |
| WO-1998002187-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ACID ADDITION SALT OF BASIC DRUG | FARMARC NEDERLAND B.V. (NL) | 1998-01-22 | — | — | WO | claimed |
| US-6255502-B1 | DRUG DELIVERY THROUGH SKIN, INTESTINAL, ORAL, NASAL, AND RECTAL MUCOSA ENHANCED BY FORMING INCLUSION COMPLEXES WITH CYCLODEXTRINS (SOLUBILIZERS/STABILIZERS) AND ACID-ADDITION SALTS OF DRUGS (CODEINE) AND A FATTY/BILE ACID | FARMARC NEDERLAND B.V. (NL) | 2001-07-03 | — | — | US | disclosed |
| EP-1024833-A1 | Pharmaceutical composition containing acid addition salt of basic drug | FARMARC NEDERLAND B.V. (NL) | 2000-08-09 | — | — | EP | disclosed |
| CN-1230123-A | Inclusion complex containing indole selective serotonin agonist | FARMARC NEDERLAND BV (NL) | 1999-09-29 | — | — | CN | disclosed |
| WO-1998002187-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ACID ADDITION SALT OF BASIC DRUG | FARMARC NEDERLAND B.V. (NL) | 1998-01-22 | — | — | WO | disclosed |